Article
MIB1 in gliomas and gliosis
Search Medline for
Authors
-
Anne Jarstein Skjulsvik
- St. Olavs Hospital, Department of Pathology and Medical Genetics, Trondheim, Norway; NTNU, Norwegian University of Science and Technology, Department of Laboratory Medicine, Children’s and Women’s Health, Trondheim, Norway
-
Sverre Helge Torp
- St. Olavs Hospital, Department of Pathology and Medical Genetics, Trondheim, Norway; NTNU, Norwegian University of Science and Technology, Department of Laboratory Medicine, Children’s and Women’s Health, Trondheim, Norway
| Published: | September 14, 2016 |
|---|
Outline
Text
Objectives: We aimed to evaluate whether the proliferation marker MIB1 could be useful in distinguishing between gliomas and gliosis in various conditions.
Materials & Methods: All samples from patients (>18 years) undergoing brain surgery in central Norway in the period of 2006- 2012 with gliosis were included. A selection of glioma samples (WHO-grade I-III) from the same period was used for comparison. Cases with small biopsy size, no visible gliosis and cases with too much inflammation were excluded.
In total, 74 biopsies of neoplastic and non-neoplastic central nervous system lesions were included: non-neuroglial neoplasms (n=37), infections (n=3), demyelinating disease (n=1), vascular malformations (n=9), vasculitis (n=1), normal brain biopsies (n=11), and astrocytomas of World Health Organization Grades I to III (n=12).
Non-neuroglial neoplasms (n =37) included metastasis from adenocarcinoma (n =11), non-small cell lung carcinoma (NSCLC) (n=14), small cell lung carcinoma (SCLC) (n=3), squamous cell carcinoma (SCC) (n=1), malignant melanoma (MM) (n=4), hemangioblastoma (n=1), renal cell carcinoma (RCC) (n=2) and urothelial carcinoma (n=1).
Results: MIB1 proliferation index was significantly higher in gliomas than in non-glioma diagnoses (Mann-Whitney U, p=0.002). Box-plot showing proliferation index across different diagnoses is shown in Figure 1 [Fig. 1].
Conclusion: Although MIB1 proliferation index were significantly higher in gliomas than in other conditions with gliosis, there is a considerable overlap in the distribution of MIB1 proliferation index for gliomas and for gliosis, limiting clinical usefulness.
